Adial Pharmaceuticals: Tiny Rally Masks Deep Liquidity & Valuation Risks
Adial Pharmaceuticals’ brief 3.7% rally masks thin liquidity, a shrinking market cap, and a volatile history—an early‑stage biotech with no proven product or stable growth.
- ADIAL PHARMACEUTICALS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read